PregLem Raises $26 Million

PregLem, a Geneva, Switzerland-based drug company focused on benign gynecological conditions and infertility, has raised CHF 32 million ($26m) in Series A funding. Sofinnova Partners led the deal, and was joined by NeoMed Management and MVM Life Science Partners. PregLem also announced that it has signed a licensing agreement with Ipsen (Euronext: IPN), under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only.